BNF March 2026 Update

This update contains 3 significant changes, 1 new monograph, 2 new preparations, and 1 deleted monograph.

Significant Changes:

• Antibacterials, use for prophylaxis: updated guidance for endoscopic retrograde cholangiopancreatography, transrectal prostate biopsy, and transurethral resection of prostate.
• Migraine: updated guidance on management.
• Obeticholic acid: new guidance for use in hepatic impairment.

New Monographs:

• Blenrep® [belantamab mafodotin].

New Preparations: Ocrevus® [ocrelizumab]; Vevizye® [ciclosporin].

Deleted Monographs: Felbinac.